Abbreviated Name

US-Turkey

Lead Investigator

Pass, Harvey Ira — New York University School of Medicine

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Pass, Harvey Ira — New York University School of Medicine
• Srivastava, Sudhir — National Cancer Institute

Abstact

We propose to test prospectively the sensitivity and specificity of cell free serum levels of SMRP in the high-risk mesothelioma cohort of Cappadocia. This study would represent a collaboration between the Turkish Ministry of Health and the National Cancer Institute of the United States represented by the University of Hawaii (Michele Carbone MD, PhD), the Early Detection Research Network (EDRN) Mesothelioma Discovery Laboratory of NYU (Harvey Pass MD), and the Data Management and Coordinating Center (DMCC) of EDRN. This prospective study will be conducted in the Cappadocian villages for the following reasons: 1. In these villages there is a unique very high incidence of mesothelioma never seen in any other part of the world. The very high mesothelioma incidence will allow us to obtain biomarker data in a relatively short time at a fraction of the costs required to follow a sufficiently large cohort in the USA that would produce the same incidence. The incidence of mesothelioma in the Western World is about 1-2/106 individuals; in the Cappadocian villages is about 1.5/100. 2. The preliminary results demonstrate the feasibility of the study. 3. Drs. Carbone and Pass have a proven track record of working with this cohort; moreover, they have the full support of Dr. Murat Tuncer, who is the Director of the Office of Cancer Control at the Turkish Ministry of Health, and who oversees blood collection performed by Turkish physicians and plans to open a Mesothelioma Clinic in the Turkish village to conduct this research.

Aims

study never launched

Analytic Method

study never launched

Outcome

We propose to test prospectively the sensitivity and specificity of cell free serum levels of SMRP in the high-risk mesothelioma cohort of Cappadocia. This study would represent a collaboration between the Turkish Ministry of Health and the National Cancer Institute of the United States represented by the University of Hawaii (Michele Carbone MD, PhD), the Early Detection Research Network (EDRN) Mesothelioma Discovery Laboratory of NYU (Harvey Pass MD), and the Data Management and Coordinating Center (DMCC) of EDRN. This prospective study will be conducted in the Cappadocian villages for the following reasons: 1. In these villages there is a unique very high incidence of mesothelioma never seen in any other part of the world. The very high mesothelioma incidence will allow us to obtain biomarker data in a relatively short time at a fraction of the costs required to follow a sufficiently large cohort in the USA that would produce the same incidence. The incidence of mesothelioma in the Western World is about 1-2/106 individuals; in the Cappadocian villages is about 1.5/100. 2. The preliminary results demonstrate the feasibility of the study. 3. Drs. Carbone and Pass have a proven track record of working with this cohort; moreover, they have the full support of Dr. Murat Tuncer, who is the Director of the Office of Cancer Control at the Turkish Ministry of Health, and who oversees blood collection performed by Turkish physicians and plans to open a Mesothelioma Clinic in the Turkish village to conduct this research.

Publications

• No publications available at this time for this protocol.

Biomarkers

• No biomarkers available at this time for this protocol.

Data Collections

• No data collections available at this time for this protocol.

Start Date

Dec 1 2010

Estimated Finish Date

Dec 1 2013

Finish Date

Aug 31 2011

Protocol ID

326

Protocol Type

Validation

Field of Research

Epigenomics

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung